Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991179 | PMC |
| http://dx.doi.org/10.4103/0301-4738.187676 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Severity of Prostaglandin-Associated Periorbitopathy Did Not Affect the Surgical Effectiveness of the Ahmed Glaucoma Valve.
J Clin Med
December 2024
Department of Ophthalmology, Shimane University Faculty of Medicine, Izumo 693-8501, Japan.
: To report the role of prostaglandin-associated periorbitopathy (PAP) severity on the surgical efficacy of Ahmed Glaucoma Valve (AGV) implantation. : Retrospective observational case series. Participants were the consecutive 102 eyes from 102 Japanese subjects (55 males, 47 females; mean age ± standard deviation, 74.
View Article and Find Full Text PDFBleb Reformation After Lateral Cantholysis in a Case of Prostaglandin-associated Periorbitopathy.
Ophthalmic Plast Reconstr Surg
December 2024
Department of Oculoplastic, Orbital & Lacrimal Surgery, Aichi Medical University Hospital, Nagakute, Aichi, Japan.
An 84-year-old male with uncontrolled intraocular pressure (IOP), despite maximum topical medications including prostaglandin F2α analog, had bilateral prostaglandin-associated periorbitopathy-related tight upper eyelids. One day after trabeculectomy of the left eyelid, IOP was 24 mm Hg, with a flat bleb. Daily ocular massage failed to maintain bleb filtration.
View Article and Find Full Text PDFChanges in prostaglandin-associated periorbital syndrome: a self-controlled and prospective study.
Cutan Ocul Toxicol
December 2024
Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China.
Article Synopsis
- The study investigated the incidence of the prostaglandin-associated periorbital syndrome (PAPS) in patients with primary open-angle glaucoma or ocular hypertension after using topical prostaglandin analogues (PGAs) for 3-6 months.
- Among the 55 patients studied, key indicators such as interpupillary distance and exophthalmos were measured, alongside subjective assessments of periocular changes, showing significant changes primarily at the 1 and 3-month marks.
- Results indicated that bimatoprost resulted in the highest incidence of PAPS, with noticeable periorbital changes like eyelash growth and hyperpigmentation increasing over time.
Evaluation of the Effect of Topical Prostaglandin Analog Treatment on Orbital Structures in Open-Angle Glaucoma with Computed Tomography.
J Clin Med
September 2024
Department of Radiology, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey.
: This study aims to evaluate the computed tomography (CT) scans of glaucoma patients using prostaglandin analogs (PGA) in one eye, investigate findings associated with prostaglandin-associated periorbitopathy (PAP), and compare these findings with those of the contralateral eyes. : Patients with open-angle glaucoma who had CT images of the orbital region taken for another reason at least one month after starting PGA treatment in one eye were included in the study. Enophthalmos measurements from thin-slice CT images, along with 3D volume measurements of orbital fat tissue, periorbital muscles, and the optic nerve, were performed.
View Article and Find Full Text PDFClinical Staging of Prostaglandin-Associated Periorbitopathy Syndrome in Glaucoma: A Review from Asia.
Semin Ophthalmol
August 2024
School of Clinical Medicine, Department of Ophthalmology, The University of Hong Kong, Hong Kong.
Purpose: Topical prostaglandin analogues are commonly used to treat patients with glaucoma, but may cause periocular and periorbital complications known as prostaglandin-associated periorbitopathy syndrome (PAPS).
Methods: A literature review was conducted on PAPS. Given the lack of consensus on grading PAPS, glaucoma specialists from Asia convened to evaluate current PAPS grading systems and propose additional considerations in grading PAPS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!